Related Experiment Video

Updated: Jun 27, 2026

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

[Metformine induces false-positive (18)F-FDG PET/CT uptake]

Benoît Brihaye1, Olivier Lidove, David Lussato

  • 1Médecine interne, Groupe hospitalier Bichat-Claude Bernard, F-75877 Paris Cedex 18, France. benoit.brihaye@bch.aphp.fr

Presse Medicale (Paris, France : 1983)
|November 28, 2008
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Experiment Videos

Last Updated: Jun 27, 2026

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Articles linked to this work by shared authors, journal, and citation graph.

Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.

Journal for immunotherapy of cancer·2026

Simultaneous integrated boost vs sequential boost chemoradiotherapy in anal squamous cell carcinoma: Association with improved disease-free survival and the role of treatment delivery parameters.

Clinical and translational radiation oncology·2026

Predicting severe toxicities and mortality in older patients with colorectal cancer: An analysis of 3 clinical trials and 3 prospective cohorts.

European journal of cancer (Oxford, England : 1990)·2026

High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched study.

Journal of autoimmunity·2026

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

AI-driven volumetric approach for automatic chemotherapy response assessment in colorectal liver metastases.

European radiology·2026

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026

Artificial intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026

Artificial Intelligence in medical research and publishing: Progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026

Beyond one-size-fits-all: Personalising health communication to drive real behaviour change.

Presse medicale (Paris, France : 1983)·2026

Secondary Staphylococcus capitis Infection of a Long-Standing Non-Coronary Sinus of Valsalva-to-Right Atrial Fistula Initially Misdiagnosed as a Gerbode Defect: A Case Report.

Journal of clinical medicine·2026

Retraction notice to "Mathematical modeling and QSPR analysis of hepatitis treatment drugs through connection indices an innovative approach" [Heliyon 11 (2025) e41234].

Heliyon·2026

Retraction notice to "The gingival crevicular fluid biomarkers with micropulse vibration device: A pilot study" [Heliyon 10 (2024) e31982].

Heliyon·2026

Retraction notice to "A review on surface modification of nanofibrous textiles for diverse applications: Focus on medical uses" [Heliyon 11 (2025) e41863].

Heliyon·2026

Moraxella nonliquefaciens Keratitis Due to Ocular Surface Disease in a Patient Treated with Zanubrutinib for Mantle Cell Lymphoma.

Eye & contact lens·2026

Retraction notice to "Rapid cutaneous remission response to tofacitinib and systemic corticosteroids in VEXAS syndrome with a novel UBA1 mutation" [JAAD Case Reports 68 (2026) 105-107].

JAAD case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us